BSX - Boston Scientific Corporation

NYSE - NYSE Delayed Price. Currency in USD
36.56
+0.41 (+1.13%)
At close: 4:01PM EST

36.56 0.00 (0.00%)
After hours: 5:19PM EST

Stock chart is not supported by your current browser
Previous Close36.15
Open36.59
Bid34.17 x 1100
Ask0.00 x 4000
Day's Range36.16 - 36.95
52 Week Range24.79 - 39.44
Volume5,806,524
Avg. Volume7,639,151
Market Cap50.592B
Beta (3Y Monthly)0.96
PE Ratio (TTM)75.69
EPS (TTM)0.48
Earnings DateJan 30, 2019 - Feb 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.41
Trade prices are not sourced from all markets
  • PR Newswire4 hours ago

    Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation

    Delaware Court Rules Edwards Lifesciences Infringes Boston Scientific Patent MARLBOROUGH, Mass. , Dec. 11, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that a jury in ...

  • TheStreet.com10 hours ago

    Shire, Abbott Labs May Pace Healthcare Stocks in 2019

    Shire is a pharmaceutical company, with a wide range of products approved for use around the world. Some of the more familiar drugs the company produces include Adderall, prescribed for adult ADD, and Pentasa, used to treat Crohn's and other inflammatory bowel diseases. The company possesses both strength and weakness, and both are evident in the most recent quarterly report.

  • Will GE’s Healthcare Unit Spin-Off Increase Shareholder Wealth?
    Market Realist13 hours ago

    Will GE’s Healthcare Unit Spin-Off Increase Shareholder Wealth?

    Why Has General Electric Stock Struggled in 2018? The Healthcare segment is the fourth-largest contributor to General Electric’s total revenues. As part of the company’s major restructuring plan in June, General Electric intends to spin off the segment and turn it into a standalone entity.

  • Startup spun out of NxThera ahead of Boston Scientific deal raises $18M
    American City Business Journals15 hours ago

    Startup spun out of NxThera ahead of Boston Scientific deal raises $18M

    Maple Grove-based Francis Medical will put the funding toward clinical trials as it prepares to roughly double its 10-person staff over the next year.

  • Boston Scientific Corporation (BSX) Hedge Funds Are Snapping Up
    Insider Monkey3 days ago

    Boston Scientific Corporation (BSX) Hedge Funds Are Snapping Up

    At Insider Monkey we follow around 700 of the best-performing investors and even though many of them lost money in the last couple of months (70% of hedge funds lost money in October whereas S&P 500 ETF lost about 7%), the history teaches us that over the long-run they still manage to beat the market, […]

  • GlobeNewswire5 days ago

    Research Report Identifies CoreLogic, Altisource Portfolio Solutions S.A, Old Dominion Freight Line, Emerson Electric, Boston Scientific, and Natural Grocers by Vitamin Cottage with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Dec. 07, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • How Boston Scientific Stock Has Performed in the Past Month
    Market Realist5 days ago

    How Boston Scientific Stock Has Performed in the Past Month

    After a stellar ride from $25.32 on January 4, 2018, to $39.04 on October 2, Boston Scientific stock (BSX) has fluctuated in the past month. From $35.38 on October 29, 2018, Boston Scientific stock rose to $38.60 on November 9, 2018. Boston Scientific’s revenue grew by 7.7% from $2.22 billion in the third quarter of 2017 to $2.39 billion in the third quarter of 2018.

  • ACCESSWIRE6 days ago

    Today's Research Reports on Trending Tickers: Boston Scientific and Abbott Laboratories

    Boston Scientific’s stock moved 5.17% lower Tuesday, to close the day at $36.52. The stock recorded a trading volume of 8,966,181 shares, which was above its three months average volume of 7,581,259 shares. In the last year, Boston Scientific’s shares have traded in a range of 24.54 - 39.44.

  • PR Newswire9 days ago

    Boston Scientific to Participate in 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference

    MARLBOROUGH, Mass. , Dec. 3, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference on Wednesday, ...

  • 14 of the Best Performing Stocks in 2018
    GOBankingRates9 days ago

    14 of the Best Performing Stocks in 2018

    See which stocks made major moves in 2018.

  • Boston Scientific (BSX) Outpaces Stock Market Gains: What You Should Know
    Zacks11 days ago

    Boston Scientific (BSX) Outpaces Stock Market Gains: What You Should Know

    Boston Scientific (BSX) closed at $37.67 in the latest trading session, marking a +1.7% move from the prior day.

  • HRC or BSX: Which Is the Better Value Stock Right Now?
    Zacks13 days ago

    HRC or BSX: Which Is the Better Value Stock Right Now?

    HRC vs. BSX: Which Stock Is the Better Value Option?

  • Analysts Remain Bullish on Align Stock
    Market Realist13 days ago

    Analysts Remain Bullish on Align Stock

    In November 2018, of the total 15 analysts covering Align Technology (ALGN), 13 analysts have given Align stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Align Technology stock is 1.67 with a target price of $317.36, implying an upside potential of 43.8% over Align Technology’s closing price of $220.71 on November 27, 2018.

  • How Is Align Technology Positioned in November?
    Market Realist13 days ago

    How Is Align Technology Positioned in November?

    Align Technology (ALGN) is focused on establishing its Invisalign clear aligners as the standard method for treating malocclusion and establishing its iTero intraoral scanner as the scanning device of choice for 3D digital scans.

  • What Investors Should Know about Align’s Operational Performance
    Market Realist13 days ago

    What Investors Should Know about Align’s Operational Performance

    For fiscal 2018 and 2019, Align Technology’s gross margins are expected at 73.97% and 73.69%, respectively, as compared with gross margins of 75.81% for fiscal 2017. In comparison, the fiscal 2018 gross margins of peers Abbott Laboratories (ABT), Boston Scientific (BSX), and Edwards Lifesciences (EW) are expected at 59.29%, 72.08%, and 74.83%, respectively.

  • Edwards Lifesciences Stock: Analysts Remain Bullish
    Market Realist13 days ago

    Edwards Lifesciences Stock: Analysts Remain Bullish

    In November, among the 22 analysts covering Edwards Lifesciences (EW), 13 recommended a “buy” or higher rating, seven recommended a “hold” rating, and two recommended a “sell” or lower rating. The mean rating for Edwards Lifesciences stock is 2.32 with a target price of $161.53, which implies an upside potential of 4.5% over Edwards Lifesciences’ closing price of $154.52 on November 27.

  • Why Analysts Are Mostly Positive on Boston Scientific Stock
    Market Realist13 days ago

    Why Analysts Are Mostly Positive on Boston Scientific Stock

    Boston Scientific (BSX) stock rose from $24.79 at the close of market on December 29, 2017, to $34.80 at the close of market on November 23, 2018, reflecting a rise of ~40% year-to-date. On November 23, Boston Scientific stock closed at $34.80, a ~42% rise from its 52-week low of $24.54 on December 6, 2017.

  • Taking Stock of Edwards Lifesciences’ Performance
    Market Realist13 days ago

    Taking Stock of Edwards Lifesciences’ Performance

    A strong operational performance and steady uptick in Edwards Lifesciences’ (EW) stock price has kept investors interested in the stock in 2018. In this series, we’ll discuss Edwards Lifesciences’ financials, segmental performance, analysts’ views on the stock, and the company’s valuation metrics. Edwards Lifesciences is a leader in patient-focused solutions for structural heart disease and critical care monitoring.

  • Edwards Lifesciences’ Operational Performance
    Market Realist13 days ago

    Edwards Lifesciences’ Operational Performance

    Edwards Lifesciences’ (EW) cost of sales increased from $213.3 million in the third quarter of 2017 to $224.9 million in the third quarter. The company’s gross profit grew from $608.2 million in the third quarter of 2017 to $681.7 million in the third quarter due to the improved product mix.

  • Cramer's lightning round: Citigroup and JP Morgan are my only bank stock picks
    CNBC14 days ago

    Cramer's lightning round: Citigroup and JP Morgan are my only bank stock picks

    Jim Cramer fires off his answers to callers' stock questions, including a query on a regional banking play.

  • Boston Scientific to Participate in Citi's 2018 Global Healthcare Conference
    PR Newswire15 days ago

    Boston Scientific to Participate in Citi's 2018 Global Healthcare Conference

    MARLBOROUGH, Mass. , Nov. 27, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Citi's 2018 Global Healthcare Conference on Thursday, December 6, 2018 in New York City ...

  • Spinal-cord stimulators help some patients, injure others
    Associated Press15 days ago

    Spinal-cord stimulators help some patients, injure others

    Desperate for relief after years of agony, Jim Taft listened intently as his pain management doctor described a medical device that could change his life. Taft's stimulator failed soon after it was surgically implanted. For years, medical device companies and doctors have touted spinal-cord stimulators as a panacea for millions of patients suffering from a wide range of pain disorders, making them one of the fastest-growing products in the $400 billion medical device industry.

  • CNBC15 days ago

    Google asks for refund of campaign contribution to embattled Sen. Cindy Hyde-Smith

    Google has asked Sen. Cindy Hyde-Smith for a refund of its $5,000 campaign contribution because of controversial comments by the Mississippi Republican, who faces a runoff election against Democrat Mike Espy on Tuesday, the company confirmed to CNBC on Monday. Ernst & Young, Amgen, AT&T, Boston Scientific, Leidos, Pfizer, Union Pacific and the Office of the Commissioner of Major League Baseball have all asked Hyde-Smith to refund their contributions, in light of her comments about attending a public hanging and suppressing voter turnout.

  • What Analysts Recommend for Hologic Stock
    Market Realist16 days ago

    What Analysts Recommend for Hologic Stock

    In November 2018, of the total 20 analysts covering Hologic (HOLX), ten analysts have given the stock a “buy” or higher rating, and ten analysts have given it a “hold” rating. The mean rating for Hologic stock is 2.3 with a target price of $45.09, implying an upside potential of 8.5% over Hologic’s closing price of $41.54 on November 21, 2018.

  • A Look at Hologic’s Gross Margin Trend
    Market Realist16 days ago

    A Look at Hologic’s Gross Margin Trend

    Hologic’s (HOLX) cost of product revenues increased from $881.8 million in fiscal 2017 to $886.6 million in fiscal 2018. Its amortization on intangible assets increased from $297.1 million in fiscal 2017 to $319.4 million in fiscal 2018 due to an increase associated with the Cynosure acquisition partially offset by lower amortization expenses related to the sale of its blood screening business. The company’s gross margin contracted from 64.07% in fiscal 2017 to 62.72% in fiscal 2018.